Gabrielle Masson

Summit Therapeutics and Akeso are answering questions raised about ivonescimab's ability to translate to Western populations, though the partners have yet to share if the new findings are statistically significant.

Date: Wednesday, September 2, 2026 8am–6:10pm PDT Event Location: San Francisco, California

Date: Thursday, September 3, 2026 8am–6:10pm PDT Event Location: San Francisco, California

The addition of small molecule capacity at BeOne Medicines' Hopewell site will support the company's hematology efforts and bring total investment in the campus to more than $1 billion.

Eli Lilly's $3.8 billion play for AtaiBeckley has fueled speculation that Big Pharma is ready to embrace psychedelics. But while the acquisition does validate the drug class, analysts say it is unlikely to trigger a broad wave of Big Pharma deals.

Sanofi had hoped the acquisition of Kymab would fill a major hole that will be left as autoimmune juggernaut Dupixent heads toward a patent cliff. Now, another therapy has failed to meet expectations.

As GSK records $2.4 billion in impairment charges for the second quarter, the U.K. pharma has announced a sweeping restructure designed to save about the same amount of money over the next few years.

Reverse mergers and acquisitions remain a viable path to the public market for venture-backed biotechs, with Caldera Therapeutics and Vidya Therapeutics announcing separate deals on Wednesday to advance immunology and inflammation assets.

Strong quarterly results are prompting Bristol Myers Squibb to lift its 2026 outlook, though the company is facing another delay for key Cobenfy Alzheimer's data and a pushed-back readout for milvexian.

Moderna's norovirus vaccine failed in a Phase 3 trial, but the company still has faith in an ambitious revenue growth target thanks to ex-U.S. vaccine sales and a unanimous FDA adcomm win for mFLUSIVA.